ausblenden:
Schlagwörter:
Carcinogenesis/genetics
Carrier Proteins/genetics
Cohort Studies
DNA Methylation
*DNA Mutational Analysis
Datasets as Topic
Epistasis, Genetic
Genome, Human/*genetics
Genomics
Humans
Medulloblastoma/*classification/*genetics
Molecular Targeted Therapy
Muscle Proteins/genetics
Mutation
Oncogenes/genetics
Transcription Factors/genetics
*Whole Genome Sequencing
Wnt Proteins/genetics
Zusammenfassung:
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and 'enhancer hijacking' events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma.
